COVID-19 Vaccines Around the Globe

First reported on Dec 31, 2019, in Wuhan, Hubei Province, China, the world is in the midst of a COVID-19 pandemic. World’s leading health and research institutions including a partnership with WHO are not only working together on the response - tracking the pandemic, advising on critical interventions, distributing vital medical supplies to those in need, but also to find vaccine which is a current dire need.


Related: Six Promising COVID-19 Vaccine that are in Phase 3 of Clinical Trial

Though the world is expressing a pressing demand of vaccine, the new vaccine has to go through different stages trials, hence proving the vaccine is a benign product for human use.

In total, there are 36 vaccine candidates that are in clinical phase evaluation and other 146 candidate vaccines in preclinical evaluation.

Here is the list of 36 vaccines that are being designed around the globe and are in phase 3 of their trial with their respective details.

  1. University of Oxford/AstraZeneca is designing a Non-Replicating Viral Vector vaccine, called ChAdOx1 nCoV-19. Interim report of phase 1/2 was published in The Lancet on July 20, 2020. The clinical trials registry of phase 1/2 can be found hereSimilarly, 'A phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 was registered on 2020-001228-32 under EU clinical trials register. In addition, on 11 June 2020, they were assigned for the phase 3 study (ISRCTN89951424, NCT04516746NCT04540393).

  2. CanSino Biological Inc. and Beijing Institute of Biotechnology are working on designing an Adenovirus Type 5 Vector vaccine and the phase 1 (ChiCTR2000030906) study (safety, tolerability, and immunogenicity) study was published on The Lancet on May 22, 2020. Similarly, phase 2 (ChiCTR2000031781) study report can be found here and details of phase 3 are can be found on NCT04526990, and on NCT04540419.

  3. A Russian based medical research institute, Gamaleya Research Institute is designing a COVID-19 vaccine, named Gam-COVID-Vac. The phase 1 open study of the candidate vaccine can be found at NCT04436471 and NCT04437875. The phase 1 study report was published on The Lancet. Similarly, the phase 3 details are here.

  4. A pharmaceutical company owned by Johnson & Johnson - Janssen Pharmaceutical Companies, is working on a Non-Replicating Viral Vector vaccine candidate, biological named Ad26.COV2.S (other names JNJ-78436735/Ad26COVS1) which already entered into its phase 3 trial (NCT04505722). Phase 1/2 study details can be found here.

  5. Sinovac is in the third phase (NCT04456595, 669/UN6.KEP/EC/2020) of the trail of its vaccine candidate, CoronaVac. The phase III clinical trial seeks to test the efficacy and safety of CoronaVac in Turkey and aims to be a pivotal study to support the licensure of this product. Phase 1/2 study can be found at NCT04383574NCT04352608NCT04551547.

  6. Wuhan Institute of Biological Products/Sinopharm: phase 1/2 (ChiCTR2000032459) and phase 3 (ChiCTR2000034780). Interim Report from phase 1/2 can be found here.

  7. Beijing Institute of Biological Products/Sinopharm: phase 1/2 (ChiCTR2000032459) and phase 3 (ChiCTR2000034780).

  8. Moderna/NIAID: phase 1 (NCT04283461), phase 2 (NCT04405076), phase 3 (NCT04470427). The interim report can be found here.

  9. BioNTech/Fosun Pharma/Pfizer: phase 1/2 (2020-001038-36ChiCTR2000034825NCT04537949). The study report was published in Nature on 12 August 2020. Details of phase 3 study can be found here.

  10. Novavax is designing a full-length recombinant SARS CoV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M. A study report from phase 1/2 (NCT04368988) was published in The England Journal of Medicine on September 2, 2020. Details of phase 2 can be found here.

  11. Anhui Zhifei Longcom Biopharmaceutical/Institute of Microbiology, Chinese Academy of Sciences: phase 1 (NCT04445194), phase 1/2 (NCT04550351), phase 2 (NCT04466085).

  12. Curevac: Phase 1 (NCT04449276), Phase 2 (NCT04515147).

  13. Institute of Medical Biology, Chinese Academy of Medical Sciences: phase 1 (NCT04412538), phase 1/2 (NCT04470609).

  14. Research Institute for Biological Safety Problems, Rep of Kazakhstan: phase 1/2 (NCT04530357).

  15. Inovio Pharmaceuticals/ International Vaccine Institute: phase 1/2 (NCT04447781NCT04336410).

  16. Osaka University/ AnGes/ Takara Bio: phase 1/2 (NCT04463472, NCT04527081).

  17. Cadila Healthcare Limited: phase 1/2 (CTRI/2020/07/026352).

  18. Genexine Consortium: phase 1/2 (NCT04445389).

  19. Bharat Biotech: phase 1/2 (NCT04471519).

  20. Kentucky Bioprocessing, Inc: phase 1/2 (NCT04473690).

  21. Sanofi Pasteur/GSK: phase 1/2 (NCT04537208).

  22. Arcturus/Duke-NUS: phase 1/2 (NCT0448095).

  23. ReiThera/LEUKOCARE/Univercells: phase 1 (NCT04528641).

  24. Clover Biopharmaceuticals Inc./GSK/Dynavax: phase 1 (NCT04405908).

  25. Vaxine Pty Ltd/Medytox: phase 1 (NCT04453852).

  26. University of Queensland/CSL/Seqirus: phase 1 (ACTRN12620000674932ISRCTN51232965).

  27. Medigen Vaccine Biologics Corporation/NIAID/Dynavax: phase 1 (NCT04487210).

  28. Instituto Finlay de Vacunas, Cuba: phase 1 (IFV/COR/04).

  29. FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo: phase 1 (NCT04527575).

  30. West China Hospital, Sichuan University: phase 1 (ChiCTR2000037518).

  31. University Hospital Tuebingen: phase 1 (NCT04546841).

  32. Institute Pasteur/Themis/Univ. of Pittsburg CVR/Merck Sharp & Dohme: phase 1 (NCT04497298).

  33. Beijing Wantai Biological Pharmacy/ Xiamen University: phase 1 (ChiCTR2000037782).

  34. Imperial College London: phase 1 (ISRCTN17072692).

  35. People's Liberation Army (PLA) Academy of Military Sciences/Walvax Biotech: phase 1 (ChiCTR2000034112).

  36. Medicago Inc.: phase 1 (NCT04450004).